(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 September 2011 (15.09.2011)

PCT

(10) International Publication Number
WO 2011/112871 A1

(51) International Patent Classification:
A61K 39/145 (2006.01) *A61K 39/39* (2006.01)

(21) International Application Number:
PCT/US2011/027993

(22) International Filing Date:
10 March 2011 (10.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/313,101 11 March 2010 (11.03.2010) US

(71) Applicant *(for all designated States except US)*: **IMMUNE DESIGN CORP.** [US/US]; Suite 700, 1124 Columbia Street, Seattle, Washington 98104 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CLEGG, Christopher, H.** [US/US]; Suite 700, 1124 Columbia Street, Seattle, Washington 98104 (US). **REED, Steven, G** [US/US]; Suite 700, 1124 Columbia Street, Seattle, Washington 98104 (US). **VAN HOEVEN, Neal** [US/US]; Suite 700, 1124 Columbia Street, Seattle, Washington 98104 (US).

(74) Agent: **NOTTENBURG, Carol**; Cougar Patent Law, 264 Seneca P1 NW, Renton, WA 98057 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: VACCINES FOR PANDEMIC INFLUENZA




FIG. 3A

(57) Abstract: Pharmaceutical and vaccine compositions comprise recombinant hemagglutinin from a pre-pandemic or pandemic influenza virus and an adjuvant comprising GLA. A particularly relevant pre-pandemic influenza virus is H5N1. Kits and methods of using the compositions are also provided.

WO 2011/112871 A1

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*